High FSHR expression in all ovarian cancer patients was linked with higher progression-free survival (PFS, Hazard ratio, HR, 0.79; 95% CI 0.68–0.9, p < 0.0001, Figure 3a) and OS (HR 0.85; 95% CI 0.75–0.97, p = 0.014, Figure 3b). This evidence concerns the gene FSHR and ovarian cancer.